Adaptation to chronic exposure to sepantronium bromide (YM155), a prototypical survivin suppressant is due to persistent DNA damage-response in breast cancer cells

Sepantronium bromide (YM155), originally developed against the anti-apoptotic protein survivin, performed exceptionally well in pre-clinical and phase I clinical trials. However, in phase II trials of several cancer types including breast cancer it performed poorly. Additionally, no definitive corre...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncotarget
Autori principali: Wani, Tasaduq H., Surendran, Sreeraj, Mishra, Vishnu S., Chaturvedi, Jaya, Chowdhury, Goutam, Chakrabarty, Anindita
Natura: Artigo
Lingua:Inglês
Pubblicazione: Impact Journals LLC 2018
Soggetti:
Research Paper
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6173358/
https://ncbi.nlm.nih.gov/pubmed/30323901
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.26096
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi